| 1 |
32988919 | Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. | 2020 Oct |
1 |
| 2 |
30743996 | HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. | 2019 Feb 8 |
2 |
| 3 |
31234033 | Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line. | 2019 Oct |
1 |
| 4 |
27791982 | ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells. | 2017 Jan 24 |
6 |
| 5 |
27611952 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. | 2016 Oct 18 |
1 |
| 6 |
27659302 | A bead-based western for high-throughput cellular signal transduction analyses. | 2016 Sep 23 |
1 |
| 7 |
23652204 | A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. | 2013 May 7 |
1 |
| 8 |
19287975 | Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. | 2009 Apr |
2 |
| 9 |
18212337 | Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. | 2008 Mar 1 |
1 |